Insider buying last 90 days
No open-market insider purchases were filed for LIVN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
LivaNova's week was dominated by third-quarter results and raised guidance. The company reported revenue of $393.1 million, up 9.9%, with adjusted EPS of $1.23, beating consensus by $0.17. Growth was driven by double-digit gains in both the Cardiopulmonary and epilepsy businesses, prompting LivaNova to raise its full-year 2026 revenue growth guidance to 9%–10% and adjusted EPS guidance to $4.40–$4.50. Operating income for the quarter fell to $28.425 million from $54.012 million, which coverage attributed largely to higher litigation provision expenses. The company also presented at the UBS Global Healthcare Conference.
The stock closed at $92.61, up 2.9% on the day, and sits well above both its 50-day average of $79.52 and 200-day average of $73.65, with the shorter average above the longer one. The GekkoIndex reading of 42.2 places the stock in the Distribution zone, down 12.6 over five days. Price stands 10.5% above Gekko Fair Value of $83.78.
The next earnings date is 24 February 2027, 101 days away and outside a typical 20-trading-day hold. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows, and billionaire holders are recorded at zero. Analyst coverage from 6 firms is entirely rated buy, with a consensus target of $90.55, implying a -2.2% consensus upside from current levels. Seasonally, the next 20 trading days have averaged +2.8% over 5 years, rising in 2 of those years, a mixed historical pattern worth noting alongside the Distribution reading.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
LivaNova scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed0 headwinds
Above 50 and 200-day
Close $91.32 is above the 50-day ($80.32) and 200-day ($74.18) averages, and the 50-day is above the 200-day.
See the chart47.8, Neutral
Reading 47.8 is in the Neutral zone.
See the GekkoIndex1.2% above
Price is within 5% of Gekko Fair Value (1.2% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 101 days
Next report Feb 24, 2027, 101 days away — outside a typical 20-trading-day hold.
See earnings+3.8% on average
From this point in the calendar, the next 20 trading days averaged +3.8% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
LivaNova closed at $91.32 on Nov 13, 2026, +61.3% over the past year, inside a 52-week range of $52.37 to $99.38.
Use the left and right arrow keys to read daily values.
Put LIVN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
LivaNova develops and manufactures medical devices used in heart, lung, and nerve-related treatments. It is best known for its VNS Therapy System, an implanted device that stimulates the vagus nerve to help patients with drug-resistant epilepsy, hard-to-treat depression, and obstructive sleep apnea. The company also makes equipment used during heart-lung procedures, including oxygenators, heart-lung machines, and perfusion systems, along with temporary life support tools for cardiopulmonary and respiratory care.
The business is organized into three areas: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. Within Neuromodulation, LivaNova is also developing the VITARIA System, which applies vagus nerve stimulation to heart failure and remains in clinical development. Its customers include perfusionists, neurologists, neurosurgeons, and other physicians, along with hospitals and healthcare providers, reached through its own sales force and independent distributors. It also works with Verily on research into clinical biomarkers for depression.
LivaNova was founded in 1987 and is headquartered in London, United Kingdom. Its shares are listed on the NASDAQ under the ticker LIVN.
LivaNova’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 47.8, in the Neutral zone, up 6.8 points over five sessions.
Up 6.8 points over five sessions, from the Distribution zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 49 | +0.6% | +3.1% | ||
| Accumulation | 213 | +1.6% | +5.1% | ||
| Neutral (current zone) | 398 | +0.1% | +0.4% | ||
| Distribution | 40 | −1.0% | −1.3% | ||
| Selling | 2 | Too few readings yet | |||
Average LIVN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
LivaNova trades 1.2% above Gekko Fair Value of $90.23, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what LivaNova shares are worth, recalculated every trading day.
$90.23
Gekko Fair Value, Nov 14, 2026
1.2% above fair value · About fair value
At the end of Aug 2026 the price was 7.1% below the estimate.
No open-market insider purchases were filed for LivaNova, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for LIVN in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in LIVN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
LivaNova has been buying back its own shares.
From company filings.
0of the funds Gekko tracks hold LIVN.
LivaNova reports on Feb 24, 2027, before the open (101 days away), and beat the EPS estimate in 8 of its last 8 reports.
Feb 24, 2027
Expected before the open, 101 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Feb 25, 2026 | $0.86 est $0.80 | $360.9M est $353.3M | +2.8% |
| Nov 5, 2025 | $1.11 est $0.92 | $357.8M est $342.7M | −8.1% |
| Jul 29, 2025 | $1.05 est $0.87 | $352.5M est $342.1M | +1.3% |
| Apr 29, 2025 | $0.88 est $0.49 | $316.9M est $330.9M | −1.4% |
| Feb 19, 2025 | $0.81 est $0.80 | — | +1.7% |
| Oct 30, 2024 | $0.90 est $0.72 | $318.1M est $323.6M | −2.5% |
| Jul 31, 2024 | $0.93 est $0.78 | $318.6M est $304.2M | −5.8% |
| May 1, 2024 | $0.73 est $0.49 | $294.9M est $304.2M | +12.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for LivaNova is $105.09, +15.1% from the last close, from 6 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 6 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 9 | Barclays | $120 | +31.4% |
| Nov 5 | Barclays | $105 | +15.0% |
| Nov 5 | Mizuho Securities | $115 | +25.9% |
| Nov 5 | Robert W. Baird | $111 | +21.6% |
| Nov 4 | Needham | $112 | +22.6% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, LivaNova averaged +3.8% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.5% | 2 of 5 |
| Next 10 trading days | +0.6% | 2 of 5 |
| Next 15 trading days | +0.5% | 2 of 5 |
| Next 20 trading days | +3.8% | 3 of 5 |
| Next 30 trading days | +3.4% | 4 of 5 |
For scale, LIVN’s typical 20-trading-day move in either direction is about 6.3%.
LivaNova’s market cap is $5.03B, with a P/E ratio of 26.3 and revenue of $1.51B over the last twelve months.
Coverage of LivaNova this week reads neutral: 2 positive, 4 neutral and 1 negative headlines.
LivaNova’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 15.0% above |
| ABTAbbott Laboratories | Neutral | 10.5% below |
| DHRDanaher | Neutral | 4.7% above |
| ISRGIntuitive Surgical | Neutral | 17.5% above |
| MDTMedtronic | Neutral | 14.2% below |
| SYKStryker | Neutral | 0.1% below |
A peer links to its own page where one exists.
LivaNova’s market cap is $5.03B at the Nov 13, 2026 close of $91.32, with 55.09M shares outstanding. The shares trade on a P/E ratio of 26.3.
The consensus analyst 12-month price target for LivaNova is $105.09, +15.1% from the last close. Of the 6 firms that rated the stock in the last 90 days, 6 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate LivaNova is about fair value: the Nov 13, 2026 close of $91.32 is 1.2% above Gekko Fair Value of $90.23. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
LivaNova is expected to report on Feb 24, 2027, before the market opens (101 days away). Analysts expect earnings of $0.98 per share on revenue of $389.2M. LivaNova beat the earnings estimate in 8 of its last 8 reports, moving 4.6% on average across the report.
LivaNova’s 52-week high is $99.38 and its 52-week low is $52.37; it closed at $91.32 on Nov 13, 2026, +61.3% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.